2024
National HIV and HCV Screening Rates for Hospitalized People who Use Drugs Are Suboptimal and Heterogeneous Across 11 US Hospitals
Westgard L, Sato T, Bradford W, Eaton E, Pilcher F, Hale A, Singh D, Martin M, Appa A, Meyer J, Weimer M, Barakat L, Felsen U, Akiyama M, Ridgway J, Grussing E, Thakarar K, White A, Mutelayi J, Krsak M, Montague B, Nijhawan A, Balakrishnan H, Marks L, Wurcel A. National HIV and HCV Screening Rates for Hospitalized People who Use Drugs Are Suboptimal and Heterogeneous Across 11 US Hospitals. Open Forum Infectious Diseases 2024, 11: ofae204. PMID: 38746950, PMCID: PMC11093397, DOI: 10.1093/ofid/ofae204.Peer-Reviewed Original ResearchScreening ratesHepatitis C virusTesting ratesHepatitis C virus screening ratesHIV screening ratesHIV testing ratesOpt-out testing policyHCV screening ratesStatistically significant differenceHepatitis C virus antibody testingInjection drug useAssociated with statistically significant differencesViral load testingNational HIVHospital sitesHCV antibody testingInpatient encountersUS hospitalsSignificant differenceInpatient hospitalizationU.S. hospitalsInpatient testingPWUDHospitalized peopleHospital
2022
Infectious Complications of Injection Drug Use
Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious Complications of Injection Drug Use. Medical Clinics Of North America 2022, 106: 187-200. PMID: 34823730, DOI: 10.1016/j.mcna.2021.08.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInjection drug useInjection drug use-related infective endocarditisHuman immunodeficiency virusHepatitis C virusInfectious complicationsDrug useCommon infectious complicationOpioid use disorderCommon risk factorsCause of deathOpioid overdose epidemicViral hepatitisInfective endocarditisImmunodeficiency virusClinical syndromeHIV outbreakInfectious disease epidemicsC virusRisk factorsIntravenous administrationOverdose epidemicUse disordersModel of treatmentMedical careInfectious diseases